David Weiss, MD
Rheumatology · Hattiesburg, MSNPI 1851431159
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $86,400 of the $118,112 with a category attached, or 73.2%. AbbVie accounts for 83.8% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2019 at $40,705 and has fallen 96.2% since, to $1,535 in 2025. Among rheumatology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,066 payments — averaging $110.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$99K
- Johnson & Johnson$8K
- Amgen$3K
- Novartis$1K
- Pfizer$963
- ANI Pharmaceuticals, Inc.$855
- plus $4K from 27 others
Across 102 payments — averaging $4692.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$217K
- Gilead$173K
- E.r. Squibb & Sons, L.L.C.$88K
What the payments were for
- Consulting fees$6,5106%
- Speaking & faculty fees$86,40073%
- Travel & lodging$4,5464%
- Food & beverage$20,14517%
- Education$5120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 383 | $98,933 |
| Johnson & Johnson(2 entities) | 86 | $8,111 |
| Amgen(2 entities) | 169 | $3,384 |
| Novartis | 61 | $1,382 |
| Pfizer | 81 | $963 |
| ANI Pharmaceuticals, Inc. | 37 | $855 |
| GSK | 36 | $570 |
| Fidia Pharma USA Inc. | 21 | $482 |
| Radius Health, Inc. | 41 | $467 |
| Lilly USA, LLC | 24 | $454 |
| Mallinckrodt Hospital Products Inc. | 13 | $363 |
| E.r. Squibb & Sons, L.L.C. | 19 | $314 |
| UCB, Inc. | 13 | $277 |
| Sanofi | 13 | $272 |
| Regeneron Healthcare Solutions, Inc. | 15 | $204 |
| Boehringer Ingelheim | 9 | $159 |
| Genentech USA, Inc. | 9 | $133 |
| Genentech, Inc. | 3 | $120 |
| AstraZeneca | 6 | $113 |
| Mallinckrodt Enterprises LLC | 4 | $105 |
| Aurinia Pharma U.S., Inc. | 5 | $94 |
| Ultragenyx Pharmaceutical Inc. | 2 | $48 |
| Bristol Myers Squibb | 2 | $45 |
| Sanofi-aventis U.S. LLC | 1 | $44 |
| Fresenius Kabi USA, LLC | 2 | $39 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Sandoz | 2 | $32 |
| Bioventus LLC | 2 | $31 |
| Medtronic | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| DJO, LLC | 1 | $17 |
| Qiagen, LLC | 1 | $17 |
| Orthogenrx Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rinvoq$69,091
- Humira$12,250
- SIMPONI ARIA$6,510
- STELARA$4,510
- Tremfya$2,750
- Skyrizi$2,679
- COSENTYX$116
- PURIFIED CORTROPHIN GEL$104
How this compares
$118,112 in reported general payments places this provider in the 90th percentile of 44 rheumatology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 60 | $585,666 |
| RinvoqUpadacitinib | 65 | $424,897 |
| Enbrel SureclickEtanercept | 45 | $338,389 |
| Enbrel MiniEtanercept | 40 | $303,571 |
| Humira(Cf)Adalimumab | 15 | $183,727 |
| Xeljanz XrTofacitinib Citrate | 18 | $104,733 |
| Cimzia (2 Pack)Certolizumab Pegol | 12 | $65,003 |
| MethotrexateMethotrexate Sodium | 321 | $5,830 |
| Leflunomide | 100 | $5,252 |
| Gabapentin | 286 | $3,415 |
| Hydroxychloroquine Sulfate | 85 | $3,182 |
| Febuxostat | 23 | $1,964 |
| Diclofenac Sodium | 176 | $1,785 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 116 | $1,760 |
| Risedronate Sodium | 32 | $1,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $98,933 | $608,62480 claims |
| UCB, Inc.Cimzia (2 Pack) | $277 | $65,00312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 44 rheumatology providers in Mississippi.
Other rheumatology in Hattiesburg
- Muhammad IjazHattiesburg$19K
- Imad BitarHattiesburg$18K
- Nancy HarrisonHattiesburg$16K
- Portia HarrisHattiesburg$4K
- Chris BensonHattiesburg$231
- Kirk EddlemanOxford$576K
- Jason TaylorMadison$173K
- Vikas MajithiaJackson$123K
- Matthew CarrollKeesler Afb$56K
- Neal ShparagoJackson$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.